215 related articles for article (PubMed ID: 35472072)
1. Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.
Bristol JA; Brand J; Ohashi M; Eichelberg MR; Casco A; Nelson SE; Hayes M; Romero-Masters JC; Baiu DC; Gumperz JE; Johannsen EC; Dinh HQ; Kenney SC
PLoS Pathog; 2022 Apr; 18(4):e1010453. PubMed ID: 35472072
[TBL] [Abstract][Full Text] [Related]
2. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
3. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive single cell data analysis of lymphoblastoid cells reveals the role of super-enhancers in maintaining EBV latency.
Yan B; Wang C; Chakravorty S; Zhang Z; Kadadi SD; Zhuang Y; Sirit I; Hu Y; Jung M; Sahoo SS; Wang L; Shao K; Anderson NL; Trujillo-Ochoa JL; Briggs SD; Liu X; Olson MR; Afzali B; Zhao B; Kazemian M
J Med Virol; 2023 Jan; 95(1):e28362. PubMed ID: 36453088
[TBL] [Abstract][Full Text] [Related]
5. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
6. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.
Banerjee S; Lu J; Cai Q; Saha A; Jha HC; Dzeng RK; Robertson ES
PLoS Pathog; 2013; 9(5):e1003314. PubMed ID: 23658517
[TBL] [Abstract][Full Text] [Related]
7. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
Bristol JA; Djavadian R; Albright ER; Coleman CB; Ohashi M; Hayes M; Romero-Masters JC; Barlow EA; Farrell PJ; Rochford R; Kalejta RF; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Jul; 14(7):e1007179. PubMed ID: 30052684
[TBL] [Abstract][Full Text] [Related]
8. Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1.
Matar CG; Rangaswamy US; Wakeman BS; Iwakoshi N; Speck SH
J Virol; 2014 Oct; 88(19):11600-10. PubMed ID: 25078688
[TBL] [Abstract][Full Text] [Related]
9. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
10. Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes.
Singh DR; Nelson SE; Pawelski AS; Cantres-Velez JA; Kansra AS; Pauly NP; Bristol JA; Hayes M; Ohashi M; Casco A; Lee D; Fogarty SA; Lambert PF; Johannsen EC; Kenney SC
PLoS Pathog; 2022 Oct; 18(10):e1010868. PubMed ID: 36190982
[TBL] [Abstract][Full Text] [Related]
11. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
Schmidt SC; Jiang S; Zhou H; Willox B; Holthaus AM; Kharchenko PV; Johannsen EC; Kieff E; Zhao B
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):554-9. PubMed ID: 25540416
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.
Hong GK; Kumar P; Wang L; Damania B; Gulley ML; Delecluse HJ; Polverini PJ; Kenney SC
J Virol; 2005 Nov; 79(22):13984-92. PubMed ID: 16254334
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
15. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
16. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
18. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.
Kis LL; Salamon D; Persson EK; Nagy N; Scheeren FA; Spits H; Klein G; Klein E
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):872-7. PubMed ID: 20080768
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.
Szymula A; Palermo RD; Bayoumy A; Groves IJ; Ba Abdullah M; Holder B; White RE
PLoS Pathog; 2018 Feb; 14(2):e1006890. PubMed ID: 29462212
[TBL] [Abstract][Full Text] [Related]
20. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes.
Katsumura KR; Maruo S; Takada K
J Med Virol; 2012 Mar; 84(3):504-10. PubMed ID: 22246839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
